Safety and Efficiency of γδ T Cell Against Liver Cancer

A liver tumor will be removed using tumor reducing surgery such as cryosurgery.PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.

NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 ~ 3 weeks.

Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.

Inclusion criteria

• Age: 18-75
• Karnofsky performance status >50
• Diagnosis with Liver Cancer based on histology or the current accepted radiological measures
• Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
• Will receive cryosurgery, IRE, gd T cells
• Life expectancy: Greater than 3 months
• Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion criteria

• Patients with other kinds of cancer
• History of coagulation disorders or anemia
• Patients with heart disease